TY - JOUR
T1 - Elobixibat and its potential role in chronic idiopathic constipation
AU - Acosta, Andres
AU - Camilleri, Michael
N1 - Funding Information:
MC is supported by the NIH (grant number RO1-DK92179).
PY - 2014/7
Y1 - 2014/7
N2 - Chronic idiopathic constipation is highly prevalent among adults. Bile acids (BAs) and the enterohepatic BA circulation modulate colonic secretion and motility that affect transit. BAs in the colon have a dual action as osmotic and stimulant agents. Newer agents, such as elobixibat (A3309), an inhibitor of the ileal BA transporter, have the potential to improve significantly the management of chronic constipation, with minimal adverse effects. Elobixibat modulates the enterohepatic BA circulation, enhancing the delivery of BAs to the colon where they induce secretory and motor effects. Secondary effects of the inhibition of BA absorption are reduced activation of the farnesoid X receptor, decreased secretion of fibroblast growth factor-19 into the portal circulation, and increased BA synthesis. This review focuses on the role of BAs, the enterohepatic BA circulation, and an ileal BA transporter inhibitor (elobixibat) in chronic constipation.
AB - Chronic idiopathic constipation is highly prevalent among adults. Bile acids (BAs) and the enterohepatic BA circulation modulate colonic secretion and motility that affect transit. BAs in the colon have a dual action as osmotic and stimulant agents. Newer agents, such as elobixibat (A3309), an inhibitor of the ileal BA transporter, have the potential to improve significantly the management of chronic constipation, with minimal adverse effects. Elobixibat modulates the enterohepatic BA circulation, enhancing the delivery of BAs to the colon where they induce secretory and motor effects. Secondary effects of the inhibition of BA absorption are reduced activation of the farnesoid X receptor, decreased secretion of fibroblast growth factor-19 into the portal circulation, and increased BA synthesis. This review focuses on the role of BAs, the enterohepatic BA circulation, and an ileal BA transporter inhibitor (elobixibat) in chronic constipation.
KW - A3309
KW - IBS-C
KW - bile acid transporter
KW - functional constipation
UR - http://www.scopus.com/inward/record.url?scp=84904820273&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904820273&partnerID=8YFLogxK
U2 - 10.1177/1756283X14528269
DO - 10.1177/1756283X14528269
M3 - Review article
AN - SCOPUS:84904820273
SN - 1756-283X
VL - 7
SP - 167
EP - 175
JO - Therapeutic Advances in Gastroenterology
JF - Therapeutic Advances in Gastroenterology
IS - 4
ER -